Indianapolis, IN (PRWEB) July 01, 2015
Apex Therapeutics announced today that company CEO, David Broecker provided a company update at the 2015 BIO International Convention in Philadelphia, PA.
The presentation took place on Tuesday, June 16 and provided an update on the achievement of corporate milestones and outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. A copy of the company overview can be found on the company website at http://www.apextherapeutics.com.
The company recently achieved several company milestones including:
- Granted an issued patent US#9,040,505 on a method for inhibiting pancreatic cancer through the administration of APX3330. This patent provides for exclusivity in the United States for APX3330 through September 21, 2030.
- Received positive feedback from the FDA on the IND-acceptability of preclinical, toxicology, and clinical data from a previous development program that established a well-tolerated, dose administration of APX3330 (E3330) in non-cancer indications by Eisai Pharmaceuticals (Tokyo, Japan).
- Outlined plans to initiate a phase I/IIA study in early 2016 for the development of APX3330 in the treatment of pancreatic cancer. The phase I/IIA study will initially determine the maximum-tolerated-dose in a cohort of refractory, solid tumor cancer patients, to be followed by a cohort of pancreatic cancer patients to determine anti-tumor effects.
About Apex Therapeutics.
Apex Therapeutics is a clinical-stage biotechnology company headquartered in Indianapolis, IN and is developing cancer therapeutics targeting the Ref-1 (redox effector factor-1) function of the APE1 (apurinic/apyrimidinic endonuelease) protein. This research is based on work of Dr. Mark Kelley from the Indiana University School of Medicine. Dr. Kelley is a recognized expert in the area of Ref-1/APE1 biology, a novel target in the development of therapeutics aimed at numerous proliferative diseases including cancer.
APX3330 is being developed as a potential therapeutic for the treatment of pancreatic cancer. APX3330 has been shown in numerous preclinical studies to have activity in reducing pancreatic cancer growth. Eisai Pharmaceuticals previously developed APX3330 under the project name E3330 in non-cancer indications through phase IIB development. Apex Therapeutics has the exclusive rights to the data from this previous development program for the treatment of cancer.
About Pancreatic Cancer
According to the American Cancer Society, 48,960 Americans will be diagnosed with pancreatic cancer and more than 40,560 will die from the disease. Pancreatic cancer remains one of the most deadly forms of cancer with one and five year survival rates of 25% and 5% respectively. With few effective treatments, pancreatic cancer remains an area of high unmet medical need.